About me

Dr. Emily Bergsland is a specialist in gastrointestinal oncology at the UCSF Helen Diller Family Comprehensive Cancer Center. Her expertise includes treating colorectal and other gastrointestinal cancers, and neuroendocrine tumors.

In her research, Bergsland focuses on developing and testing new cancer therapies.

Bergsland earned her medical degree at the University of Minnesota, then completed a residency and fellowship at UCSF. She joined the UCSF medical staff and faculty in 1996.

  • Education

    University of Minnesota, 1989

  • Residencies

    UCSF, Oncology, 1995

  • Fellowships

    UCSF, Internal Medicine, 1992

  • Academic Title

    Professor

Center for Neuroendocrine Tumors

Bakar Precision Cancer Medicine Building

1825 Fourth St.
San Francisco, CA 94158

Gastrointestinal Medical Oncology Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Fourth Floor
San Francisco, CA 94158

Pancreas Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Fourth Floor
San Francisco, CA 94158

My reviews

4.9

Overall Experience
199 Reviews
Dr Bergsland is the best. Dealing with a cancer diagnosis is not wonderful. Dr Bergland is extremely knowledgeable with my rare type of cancer and extremely helpful in all aspects taking the time to answer all my questions and helping me with things I didn't even know. She is amazing can not say enough wonderful things about her.
Explained things in a way that was easy to understand
199 Reviews
Did the doctor pay attention to your concerns
198 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
192 Reviews
Knew the important information about your medical history
199 Reviews
The provider showed respect for what you had to say
198 Reviews
The provider spent enough time with me
199 Reviews

Selected research

Decorative Caduceus

Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

ORR is defined as the proportion of the subjects in the analysis population who demonstrated complete response (CR) or partial response (PR) radiographically according to Response Evaluation Criteria in Solid Tumors (RECIST) versi...

Recruiting

Share